Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
Adaptive Immunity
Animals
Antibodies, Neutralizing
Antibodies, Viral
/ immunology
Antigens, Viral
/ immunology
COVID-19 Vaccines
/ immunology
Coronavirus Nucleocapsid Proteins
/ immunology
Genetic Vectors
/ immunology
Humans
Immunity, Cellular
Mice
Phosphoproteins
/ immunology
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Vaccines, Attenuated
/ immunology
Vaccines, Synthetic
/ immunology
Vaccinia virus
/ immunology
Viral Vaccines
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 11 2020
30 11 2020
Historique:
received:
05
07
2020
accepted:
02
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
Identifiants
pubmed: 33257686
doi: 10.1038/s41467-020-19819-1
pii: 10.1038/s41467-020-19819-1
pmc: PMC7705736
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
COVID-19 Vaccines
0
Coronavirus Nucleocapsid Proteins
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Attenuated
0
Vaccines, Synthetic
0
Viral Vaccines
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6121Subventions
Organisme : NIAID NIH HHS
ID : U19 AI128913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181045
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA107399
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : UpdateOf
Références
J Gen Virol. 2007 Dec;88(Pt 12):3249-3259
pubmed: 18024893
J Virol. 2013 Feb;87(3):1322-32
pubmed: 23152525
J Virol. 2018 Sep 12;92(19):
pubmed: 30045984
PLoS One. 2018 Jan 19;13(1):e0188453
pubmed: 29351298
J Virol. 2004 Apr;78(8):3965-76
pubmed: 15047812
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):9977-81
pubmed: 1438247
Nat Rev Immunol. 2020 Sep;20(9):519
pubmed: 32686754
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
J Vis Exp. 2019 Mar 1;(145):
pubmed: 30882796
Int Immunol. 2003 Jun;15(6):765-72
pubmed: 12750360
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Blood. 2017 Jan 5;129(1):114-125
pubmed: 27760761
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Virology. 1997 Nov 24;238(2):198-211
pubmed: 9400593
J Virol. 2020 Jun 16;94(13):
pubmed: 32546606
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Vaccine. 2013 Sep 6;31(39):4247-51
pubmed: 23523407
PLoS Pathog. 2014 Nov 20;10(11):e1004524
pubmed: 25412505
J Mol Biol. 1988 Feb 5;199(3):399-413
pubmed: 3351934
J Virol. 1990 Oct;64(10):5029-35
pubmed: 2398534
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
J Virol. 1986 Aug;59(2):249-59
pubmed: 3016294
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Exp Med. 2005 Jan 3;201(1):95-104
pubmed: 15623576
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51
pubmed: 1438287
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Virol. 1987 Jun;61(6):1957-63
pubmed: 3033323
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
J Virol. 2011 Oct;85(20):10582-97
pubmed: 21775467
Ann Intern Med. 2020 Mar 3;172(5):306-316
pubmed: 32040960
Vaccine. 1996 Oct;14(15):1451-8
pubmed: 8994321
Cell. 1986 Jun 20;45(6):879-84
pubmed: 3085958
Zentralbl Veterinarmed B. 1966 Feb;13(1):1-13
pubmed: 4288045
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
Virology. 1998 May 10;244(2):365-96
pubmed: 9601507
Cold Spring Harb Symp Quant Biol. 1983;47 Pt 2:723-9
pubmed: 6574869
Vaccine. 1988 Dec;6(6):504-8
pubmed: 2854339
Oncoimmunology. 2017 Aug 11;6(12):e1363138
pubmed: 29209571
EBioMedicine. 2020 May;55:102768
pubmed: 32344202
J Virol. 1994 Jan;68(1):130-47
pubmed: 8254722
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nucleic Acids Res. 1979 Nov 24;7(6):1513-23
pubmed: 388356
PLoS One. 2008 Feb 20;3(2):e1638
pubmed: 18286194
Vaccine. 2010 Feb 10;28(6):1547-57
pubmed: 19969118
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Vaccine. 2013 Sep 6;31(39):4241-6
pubmed: 23523410
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211
J Virol. 2009 Jul;83(14):7176-84
pubmed: 19420086